{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Coeptis Therapeutics Holdings, Inc."},"Symbol":{"label":"Symbol","value":"COEP"},"Address":{"label":"Address","value":"105 BRADFORD ROAD,SUITE 420 SUITE 420, WEXFORD, Pennsylvania, 15090, United States"},"Phone":{"label":"Phone","value":"1 (724) 934-6467"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively 'Coeptis'), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet."},"CompanyUrl":{"label":"Company Url","value":"https://www.coeptistx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Colleen Delaney","title":"Chief Scientific & Medical Officer"},{"name":"Daniel Yerace","title":"Director & Vice President-Operations"},{"name":"David Mehalick","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}